Cipla on Tuesday announced a partnership with ImmunoACT to commercialise talicabtagene autoleucel, an indigenously developed CAR-T cell therapy, in the Republic of South Africa, Algeria and Morocco.
Under the arrangement, Cipla, through its subsidiary Medpro Pharmaceutica, has entered into an exclusive licence and supply agreement with ImmunoACT. As part of the collaboration, ImmunoACT will be responsible for manufacturing the therapy, while Cipla will handle its commercialisation across the licensed African territories.
The Mumbai-based drugmaker said the partnership aims to expand access to this advanced treatment in markets with significant unmet medical needs, reinforcing its focus on bringing innovative and differentiated therapies to patients globally.